UGP UGP
Company Profile ↓Company Overview
UGP (UGP) is a publicly traded company listed on with a market capitalization of $6.99B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 15.7%, reflecting efficient use of shareholder capital.
Net profit has compounded at 10.9% per year over the last five years.
Trades at an undemanding P/E of 2.8.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $142.37B (+6.6% YoY); net profit $2.45B.
- Trailing 12 Months Year-on-year growth — revenue +6.6%, earnings +3.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -0.3%, profit CAGR 10.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -0.29% |
| 1 Year: | 6.64% |
Compounded Profit Growth
| 5 Years: | 10.86% |
| 1 Year: | 3.86% |
Stock Price Performance
| 1 Year: | +104.58% |
| 6 Months: | +26.21% |
| 3 Months: | +4.51% |
| 1 Month: | +14.86% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.43 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 10.9% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -0.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 33.33B | 34.06B | 37.03B | 37.95B | 36.75B |
| Cost of Revenue | - | 31.19B | 31.91B | 34.56B | 35.36B | 33.58B |
| Gross Profit | - | 2.14B | 2.15B | 2.48B | 2.59B | 3.17B |
| Operating Expenses | - | 1.23B | 737.85M | 1.05B | 1.46B | 1.35B |
| Operating Income | - | 909.11M | 1.41B | 1.43B | 1.13B | 1.82B |
| EBITDA | - | 1.29B | 2.60B | 2.26B | 1.72B | 2.64B |
| Interest Expense | - | 371.46M | 675.78M | 774.47M | 646.01M | 792.25M |
| Pretax Income | - | 611.05M | 1.53B | 1.03B | 642.98M | 1.41B |
| Tax Provision | - | 247.87M | 354.04M | 257.41M | 204.37M | 498.26M |
| Net Income | - | 332.85M | 1.09B | 709.19M | 323.45M | 875.57M |
| Diluted EPS | - | 0.30 | 0.98 | 0.64 | 0.30 | 0.80 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 143.63B | 126.05B | 133.50B | 142.37B |
| Cost of Revenue | - | 136.28B | 116.73B | 123.81B | 133.01B |
| Gross Profit | - | 7.36B | 9.32B | 9.69B | 9.36B |
| Operating Expenses | - | 4.20B | 4.97B | 4.80B | 4.51B |
| Operating Income | - | 3.16B | 4.35B | 4.89B | 4.85B |
| EBITDA | - | 4.50B | 6.36B | 6.59B | 7.81B |
| Interest Expense | - | 1.59B | 1.63B | 1.37B | 2.41B |
| Pretax Income | - | 1.88B | 3.58B | 4.01B | 3.81B |
| Tax Provision | - | 341.51M | 1.06B | 1.49B | 1.06B |
| Net Income | - | 1.80B | 2.44B | 2.36B | 2.45B |
| Diluted EPS | - | 1.64 | 2.21 | 2.11 | 2.24 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 36.44B | 38.25B | 39.56B | 49.35B |
| Current Assets | - | 18.56B | 18.65B | 16.05B | 19.18B |
| Cash & Equivalents | - | 5.62B | 5.93B | 2.07B | 3.18B |
| Inventory | - | 4.91B | 4.29B | 3.92B | 4.24B |
| Receivables | - | 4.33B | 4.85B | 3.54B | 3.70B |
| Total Liabilities | - | 24.27B | 24.22B | 23.73B | 31.62B |
| Current Liabilities | - | 12.77B | 11.23B | 10.49B | 11.85B |
| Long Term Debt | - | 8.39B | 9.78B | 10.38B | 15.84B |
| Total Debt | - | 13.28B | 13.30B | 15.35B | 21.83B |
| Total Equity | - | 11.71B | 13.51B | 15.16B | 15.67B |
| Shares Outstanding | - | 1.12B | 1.12B | 1.12B | 1.12B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 2.00B | 3.85B | 3.74B | 5.45B |
| Investing Cash Flow | - | 7.90B | -1.02B | -6.39B | -2.85B |
| Financing Cash Flow | - | -6.91B | -2.49B | -1.23B | -1.47B |
| Capital Expenditure | - | -1.21B | -1.29B | -1.79B | -2.01B |
| Free Cash Flow | - | 797.86M | 2.56B | 1.95B | 3.45B |
| Net Change in Cash | - | 3.39B | 333.87M | -3.89B | 1.14B |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 5.1% | 7.4% | 7.3% | 6.6% |
| Operating Margin % | - | 2.2% | 3.5% | 3.7% | 3.4% |
| Net Margin % | - | 1.3% | 1.9% | 1.8% | 1.7% |
| ROE % | - | 15.4% | 18.1% | 15.6% | 15.7% |
| ROCE % | - | 13.4% | 16.1% | 16.8% | 12.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for UGP
Ultrapar Participações (BOVESPA:UGPA3) Stock Sees Modest Fair Value Lift After Mixed Analyst Calls
The updated fair value estimate for Ultrapar Participações has shifted from about R$32.18 to roughly R$33.21, which puts recent research moves into clearer focus for you as an investor. This adjustment sits alongside price targets that rang…
Ultrapar Participações (UGP) Among the Best Undervalued Stocks Under $5
Ultrapar Participações S.A. (NYSE:UGP) is one of the Best Undervalued Stocks to Buy Under $5. The stock has gained more than 22% over the past 6 months and currently trades at a forward price to earnings ratio of 8.8, which is below the sec…
Zacks.com featured highlights include First American Financial, Caleres, Cenovus, Ultrapar and Open Text
First American Financial, Caleres, Cenovus, Ultrapar and Open Text have been highlighted in this Screen of The Week article.
UGP or WMB: Which Is the Better Value Stock Right Now?
UGP vs. WMB: Which Stock Is the Better Value Option?
Is Ultrapar Participacoes (UGP) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to u…
Tap These 5 Bargain Stocks With Amazingly Low EV-to-EBITDA Ratios
FAF, CAL, CVE, UGP and OTEX stand out with attractive EV-to-EBITDA ratios and strong earnings outlooks.
UGP — Frequently Asked Questions
What is the current share price of UGP?
As of 2026-08-05 17:25 PDT, UGP trades at $6.26 on NASDAQ/NYSE. Its 52-week range is $3.01 to $6.56.
What is the market capitalisation of UGP?
UGP has a market capitalisation of $6.99B on NASDAQ/NYSE.
What is the P/E ratio of UGP?
UGP trades at a trailing price-to-earnings (P/E) ratio of 2.79. Its price-to-book (P/B) ratio is 0.45.
What is the return on equity (ROE) of UGP?
UGP has a return on equity (ROE) of 15.66%. Its return on capital employed (ROCE) is 12.94%.
Is UGP a good stock to buy?
This page provides a data-driven analysis of UGP, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.